A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects With Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma.
Location: REDI (East Bay)
Please contact James Nasman NasmanJ@sutterhealth.org about MAGNIFY
View study details on ClinicalTrials.gov
Please note that trial statuses change frequently, for the most up to date information regarding REDI's enrolling studies; please contact the research department at 510-204-4155.
December 23, 2014